NCT00295061 - Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions

Alpha 1-Antitrypsin Deficiency

Interventions

DRUG

Alpha-1 MP

alpha-1 proteinase inhibitor (human), 60 mg/kg body weight

DRUG

alpha-1 proteinase inhibitor (human)

Prolastin

Trial Locations (8)

St Lukes-Roosevelt Hospital Center, New York, New York

Temple University Hospital, Philadelphia

Medical University of South Carolina, Charleston

University of Miami School of Medicine, Miami

Cleveland Clinic Foundation, Cleveland

National Jewish Medical and Research Center, Denver

University of Florida College of Medicine, Gainesville

University of Texas Health Center at Tyler, Tyler